TY - JOUR
T1 - Mild elevation of N-acetylaspartic acid and macrocephaly
T2 - Diagnostic problem
AU - Surendran, Sankar
AU - Bamforth, Fiona J.
AU - Chan, Alicia
AU - Tyring, Stephen K.
AU - Goodman, Stephen I.
AU - Matalon, Reuben
PY - 2003/11
Y1 - 2003/11
N2 - Patients with slightly increased excretion of N-acetylaspartic acid in urine, together with macrocephaly, present a dignostic dilemma for Canavan's disease. We describe a 13-year-old male patient with macrocephaly, mild developmental delay, increased signal intensity in the basal ganglia bilaterally, partial cortical blindness, and retinitis pigmentosa. Although the clinical course and magnetic resonance imaging findings did not resemble typical Canavan's disease, N-acetylaspartic acid excretion in the patient's urine was slightly elevated, 99.90 ± 4.00 μg/mg creatinine, whereas the normal control range was < 83 μg/mg creatinine. Cultured skin fibroblasts from the patient showed no aspartoacylase activity. Cloning of genomic DNA isolated from the patient's fibroblasts showed an intronic mutation, specifically deletion of -2A and -3C at the acceptor site of exon 3 and disrupting the normal splicing of the gene. A second mutation was found in exon 6, 863 A→G in aspartoacylase complementary DNA, causing a tyrosine-to-cysteine (Y288C) amino acid substitution. Expression of the mutation on exon 6 showed normal aspartoacylase activity. These data suggest that expression of the mutation may help to understand the enzyme defect in patient with slightly increased N-acetylaspartic acid excretion.
AB - Patients with slightly increased excretion of N-acetylaspartic acid in urine, together with macrocephaly, present a dignostic dilemma for Canavan's disease. We describe a 13-year-old male patient with macrocephaly, mild developmental delay, increased signal intensity in the basal ganglia bilaterally, partial cortical blindness, and retinitis pigmentosa. Although the clinical course and magnetic resonance imaging findings did not resemble typical Canavan's disease, N-acetylaspartic acid excretion in the patient's urine was slightly elevated, 99.90 ± 4.00 μg/mg creatinine, whereas the normal control range was < 83 μg/mg creatinine. Cultured skin fibroblasts from the patient showed no aspartoacylase activity. Cloning of genomic DNA isolated from the patient's fibroblasts showed an intronic mutation, specifically deletion of -2A and -3C at the acceptor site of exon 3 and disrupting the normal splicing of the gene. A second mutation was found in exon 6, 863 A→G in aspartoacylase complementary DNA, causing a tyrosine-to-cysteine (Y288C) amino acid substitution. Expression of the mutation on exon 6 showed normal aspartoacylase activity. These data suggest that expression of the mutation may help to understand the enzyme defect in patient with slightly increased N-acetylaspartic acid excretion.
UR - http://www.scopus.com/inward/record.url?scp=0142065924&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0142065924&partnerID=8YFLogxK
U2 - 10.1177/08830738030180111601
DO - 10.1177/08830738030180111601
M3 - Article
C2 - 14696913
AN - SCOPUS:0142065924
SN - 0883-0738
VL - 18
SP - 809
EP - 812
JO - Journal of Child Neurology
JF - Journal of Child Neurology
IS - 11
ER -